Asked by: Eric Ollerenshaw (Conservative - Lancaster and Fleetwood)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health, when he expects NHS England to publish the second quarter figures for Cancer Drugs Fund notifications and individual Cancer Drugs Fund requests for 2014-15; and if he will make a statement.
Answered by George Freeman
NHS England published quarter two 2014-15 Cancer Drugs Fund figures on its website on 19 November 2014. Further information is available at:
www.england.nhs.uk/ourwork/pe/cdf/
Since October 2010, over 60,000 patients in England have benefitted from the Cancer Drugs Fund.
Asked by: Eric Ollerenshaw (Conservative - Lancaster and Fleetwood)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health, if he will place in the Library the responses to Public Health England's consultation on drug misuse and dependence.
Answered by Jane Ellison
Public Health England (PHE) has convened an expert group, chaired by Professor John Strang, to consider the responses to the consultation on a possible update to the United Kingdom guidelines on the clinical management of drug misuse and dependence.
PHE is providing secretariat to the group, and we will place consultation responses in the Library after the expert group has had the opportunity to review them in full. The expert group has not yet determined when this will be.
Asked by: Eric Ollerenshaw (Conservative - Lancaster and Fleetwood)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health, what recent discussions he has had on the future of the National Cancer Peer Review Programme.
Answered by Jane Ellison
NHS England is currently reviewing the National Cancer Peer Review programme with a view to considering how its success might be extended into other new areas of specialised commissioning. Regardless of the outcome of this review, cancer peer review will continue to play a critical part of any broader peer review programme NHS England may look to introduce.
The number of visits undertaken by the programme changes based on how many risk visits and how many comprehensive visits are carried out. The highest number of visits completed in any one year since the programme began was 535 in 2012-13, when comprehensive visits to acute oncology were carried out. Generally, between 400 and 450 visits are completed each year.
As the programme has moved to risk assessed visits only rather than comprehensive visits (as comprehensive visits to all tumour sites have been completed) the number of visits has reduced; in 2013-14 there were 424 cancer visits.
This year, between April 2014 and October 2014, 100 cancer visits and 28 major trauma centre visits have been carried out.
Asked by: Eric Ollerenshaw (Conservative - Lancaster and Fleetwood)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health, when Public Health England plans to report on the consultation on drug misuse and dependence.
Answered by Jane Ellison
Public Health England (PHE) has convened an expert group, chaired by Professor John Strang, to consider the responses to the consultation on a possible update to the United Kingdom guidelines on the clinical management of drug misuse and dependence.
PHE will be providing an update on the plans of the expert group in winter 2014-15 following its initial meeting on 7 October 2014. The expert group plans to complete its advice to PHE and the devolved administrations by early 2016.
Asked by: Eric Ollerenshaw (Conservative - Lancaster and Fleetwood)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health, what assessment he has made of the performance of the National Cancer Peer Review Programme.
Answered by Jane Ellison
NHS England is currently reviewing the National Cancer Peer Review programme with a view to considering how its success might be extended into other new areas of specialised commissioning. Regardless of the outcome of this review, cancer peer review will continue to play a critical part of any broader peer review programme NHS England may look to introduce.
The number of visits undertaken by the programme changes based on how many risk visits and how many comprehensive visits are carried out. The highest number of visits completed in any one year since the programme began was 535 in 2012-13, when comprehensive visits to acute oncology were carried out. Generally, between 400 and 450 visits are completed each year.
As the programme has moved to risk assessed visits only rather than comprehensive visits (as comprehensive visits to all tumour sites have been completed) the number of visits has reduced; in 2013-14 there were 424 cancer visits.
This year, between April 2014 and October 2014, 100 cancer visits and 28 major trauma centre visits have been carried out.
Asked by: Eric Ollerenshaw (Conservative - Lancaster and Fleetwood)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health, if he will request that the Care Quality Commission publishes data on trends of GP practices prescribing benzodiazepine.
Answered by Norman Lamb
The Care Quality Commission (CQC) is the independent regulator of health and social care in England.
The CQC has provided the following information:
CQC are not currently conducting a review of the prescribing of benzodiazepine.
Clinical commissioning groups (CCGs) collect data on the prescribing of benzodiazepine but this is not collated nationally. The CQC would be alerted to any prescribing trends and outliers during discussions with the CCGs when a GP practice is inspected.
Asked by: Eric Ollerenshaw (Conservative - Lancaster and Fleetwood)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health, how many cancer-specific reviews were completed by the National Cancer Peer Review Programme team in each financial year since the programme began; and how many cancer-specific reviews are scheduled to be conducted by the National Cancer Peer Review Programme after the current financial year.
Answered by Jane Ellison
NHS England is currently reviewing the National Cancer Peer Review programme with a view to considering how its success might be extended into other new areas of specialised commissioning. Regardless of the outcome of this review, cancer peer review will continue to play a critical part of any broader peer review programme NHS England may look to introduce.
The number of visits undertaken by the programme changes based on how many risk visits and how many comprehensive visits are carried out. The highest number of visits completed in any one year since the programme began was 535 in 2012-13, when comprehensive visits to acute oncology were carried out. Generally, between 400 and 450 visits are completed each year.
As the programme has moved to risk assessed visits only rather than comprehensive visits (as comprehensive visits to all tumour sites have been completed) the number of visits has reduced; in 2013-14 there were 424 cancer visits.
This year, between April 2014 and October 2014, 100 cancer visits and 28 major trauma centre visits have been carried out.